ArticleScientific reports2025
Association of neutrophil-percentage-to-albumin ratio with all-cause and cardiovascular mortality in patients with diabetes and prediabetes from the NHANES 1999-2018.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Association Between Neutrophil Percentage-to-Albumin Ratio and All-Cause Mortality and Cardiovascular Events in Patients with Diabetic Foot Ulcers: A Retrospective Cohort Study.Journal of inflammation research · 2026Article
- Association between neutrophil percentage-to-albumin ratio and bone mineral density and prevalent osteoporosis in patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
- The association between sarcopenia and diabetic retinopathy: a mediation analysis of inflammatory biomarkers.Frontiers in endocrinology · 2026Article
- The association between frailty index and all-cause mortality in US individuals with kidney stones: mediation by systemic immune-inflammation (SII) index.Urolithiasis · 2025Article
- Age-stratified selection of albumin-based inflammatory ratios: a novel strategy for optimizing risk prediction of severe pneumonia in children.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The neutrophil-percentage-to-albumin ratio (NPAR) has emerged as a concise and effective biomarker for assessing systemic inflammatory status, with established prognostic value for mortality risk across various disease populations. This study aimed to elucidate the association between NPAR and both all-cause and cardiovascular mortality in patients with diabetes and prediabetes. A cohort of 8560 patients with diabetes and prediabetes was recruited from the National Health and Nutrition Examination Survey (NHANES), with mortality outcomes tracked through the National Death Index up to December 31, 2019. A weighted Cox regression model was used to evaluate the association of NPAR with all-cause and cardiovascular mortality. The restricted cubic spline (RCS) curve was used to assess the nonlinear relationship between NPAR and mortality outcomes. Subgroup analysis was conducted to evaluate the differences in the predictive performance of various NPAR features across different subgroups. Cox regression analysis indicated that participants in the highest quartile of NPAR exhibited a substantially increased risk of all-cause mortality (hazard ratio [HR] 1.54; 95% confidence interval [CI] 1.28-1.87) and cardiovascular death (HR 2.04; 95% CI 1.47-2.84) compared to the reference group. The RCS curve further illustrated a significant nonlinear correlation between NPAR and outcomes in patients with diabetes and prediabetes. NPAR can serve as a robust nonlinear predictor for both all-cause and cardiovascular mortality in individuals diagnosed with diabetes or prediabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.